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expenditure estimation. Information of physician visits, hospital admission rate, 
medical expenditure and its constitutions, length of stay were analyzed using 
STATA 11. RESULTS: A total of 612,227 insured urban employees were diabetes, 
accounting for 5.2% of population in the program of UEBMI in Beijing during 
2010.10.01 to 2011.09.30. Annual outpatient visits were37.4 times/person and the 
cost was CNY (Chinese Yuan) 388.42/visit, resulting in CNY 14526.91 for annual 
outpatient expenditure. The annual hospital admission rate of the investigated 
people with diabetes was 7.08%. For those who had used inpatient services, 
annual hospital admissions were 1.78 times/person (length of stay was 16.35 
days) and the cost was CNY 15070.99/admission, resulting in CNY 26826.37 for 
annual inpatient expenditure. The total of annual medical expenditure was 
CNY16426.21/person, of which, the cost of western drugs, Chinese traditional 
drugs, treatment, laboratory test, examination and others accounted for 48.46%, 
30.76%, 9.08%, 5.17%, 4.65% and 1.88% respectively. The cost of insulin accounts 
for 2.80% of total medical expenditure. CONCLUSIONS: The proportion of people 
with diabetes in the UEBMI program in Beijing is consistent with the high 
diabetes prevalence reported from other epidemiological studies. Diabetes is 
becoming a chronic epidemic disease with major public concern. This study 
showed that in Beijing, significant amount of societal and medical resources 
were consumed by people with diabetes. Early glycemic control and appropriate 
drug utilization should be the key to reduce the burden of diabetes.  
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ANNUAL HEALTH CARE UTILIZATION AND COSTS IN CUSHING'S DISEASE 
PATIENTS IN THE UNITED STATES  
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1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA  
OBJECTIVES: Cushing’s disease (CD) is a rare disorder resulting from 
adrenocorticotropic hormone secreting pituitary tumor; limited US data are 
available on health care utilization for this rare condition. We evaluated health 
care utilization and costs associated with CD. METHODS: We identified CD 
patients in 2010 in claims databases (Thomson Reuters MarketScan Commercial; 
IMS Health PharMetrics). Since no CD diagnosis code exists, patients were 
identified with a claim for Cushing’s syndrome and either benign pituitary 
adenomas or hypophysectomy (adenectomy) and continuous-enrollment in the 
study year. We estimated total and CD-related utilization and costs using 
pharmacy and medical claims. CD-related outcomes were determined using 
claims with primary diagnosis of Cushing’s syndrome, benign pituitary 
adenoma, or claims with CD treatment (pharmacologic/surgery/radiotherapy). 
RESULTS: We identified 685 CD patients across US (mean age: 41.7years; 81% 
female; mean Charlson-comorbidity: 1.6; mean no. chronic conditions: 4.2); 30.5% 
(209) patients had diabetes, 22.5% had psychiatric disturbances, 8.6% had 
osteoporosis, 8% had cardiovascular disease/stroke, 5.5% had kidney stones, and 
0.7% had compression fracture of vertebra. 38.4% patients had inpatient 
hospitalizations and 34.2% had emergency department visits. Patients had a 
mean of 19.8 physician office visits. CD-related hospitalization was observed in 
26.9%, emergency department visits in 0.9%, CD-treatment in 36.8%. Patients had 
mean of 3.2 CD-related visits. Mean overall costs were $34,992 (SD:$45,811; 
median:$18,031): $3,597 (SD:$6,323) were pharmacy and $31,395 (SD:$44,082) were 
medical costs. Of this total, CD-related costs accounted for $14,310 (SD:$25,161; 
median:$2,079): $9,353 (SD:$19,259) from treatment and $4,957 (SD:$11,805) from 
non-treatment costs. CONCLUSIONS: Economic burden of CD is substantial, with 
hospitalizations or emergency department visits observed in >34% patients, 19.8 
office visits/patient, and up to $35,000 in annual total cost. Direct CD-related 
costs are likely underestimated because of under-coding of CD in claims and use 
of primary diagnosis claims only. Future research should further examine CD-
comorbidity costs and impact of long-term comorbidities of CD.  
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OBJECTIVES: To assess a) the economic impact of diabetes on quality of life, 
disabilities and health utilities, the income, employment and education of patients 
and their families in Argentina, and b) compare these costs with those recorded in 
people without diabetes. METHODS: Case-control study comparing cases with 
T2DM with or without chronic complications and controls without diabetes (paired 
by age and gender) and social contexts. Data was obtained by telephone interviews 
(March-April 2011) using identical questionnaire. Interview data were 
supplemented with data obtained from clinical records to fully describe the 
subjects’ resources utilization and costs of care. Statistical analysis was done using 
ANOVA or Kruskal-Wallis and Chi-square (in proportions) tests and the SPSS 
version 15. The study had ethical clearance and all subjects provided oral informed 
consent. RESULTS: We interviewed 774 non diabetic controls, 387 people with 
T2DM without complications, and 387 people with T2DM and complications); 
mostly female (54.8% in each group). The diabetes duration in the group with 
complications was significantly higher than in the group without complications 
(8.1±8.4 vs. 10.8±9.0). Persons with T2DM with complications have significantly 
lower salaries, higher monthly expenditures (with lower expenditure/income ratio), 
lower percentage of people with university degree, higher hospitalization rate and 
resources consumption; they also have lost more working days (16.2) than those 
either with T2DM without complications (8.48) or those without T2DM (7.78). People 
with T2DM with complications have significantly higher direct medical and indirect 
cost. CONCLUSIONS: This report shows objectively the heavy burden of diabetes 
and its complications for the patient, its family, the health systems and the overall 
society in Argentina. The data provide a serious warning to health care authorities 
to strengthen the implementation of prevention strategies to reduce this burden.  
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RECENT TRENDS IN TYPE-2 DIABETES MELLITUS-RELATED INPATIENT CARE 
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OBJECTIVES: Type-2 diabetes mellitus (T2DM), the most common form of 
diabetes (>90% of all cases), is typically associated with adult obesity. Recently, 
increasing attention been given to the growing prevalence of disease among 
pediatric populations. This study assessed trends in pediatric T2DM 
hospitalization and aspects of related care in the US. METHODS: Data for 
pediatric (≤20 years) hospitalizations with a primary diagnosis of T2DM (ICD-9-
CM codes 250.x0 and 250.x2) from the 2000, 2003, 2006, and 2009 HCUP Kids’ 
Inpatient Databases were analyzed. Weighted estimates of the number of T2DM-
related hospitalizations and associated resource-based outcomes (i.e., total 
charges, length of stay [LOS]) were derived. RESULTS: Between 2000 and 2009, 
rates of pediatric T2DM-related hospitalizations (per 100,000 2010 US pediatric 
population) increased from 2.0/100,000 in 2000 to 2.7/100,000 in 2003 and 
3.5/100,000 in 2006, before falling modestly to 2.7/100,000 in 2009. Mean LOS for 
these hospitalizations remained fairly consistent over time (3.2 days in 2000, 3.3 
days in 2003, 3.1 days in 2006, and 2.9 days in 2009). Mean charges (2012 USD) for 
T2DM-related stays have increased nearly 34%, from $13,775 (2000) to $18,432 
(2009). Finally, total pediatric T2DM-related inpatient charges increased by more 
than 147% percent between 2000 and 2006, from $21.5M (2012 USD) to $53.3M, 
before falling slightly in 2009 to $42.4M. CONCLUSIONS: We observed increases 
in rates of pediatric T2DM-related hospitalization over time, with substantial 
growth in the economic burden associated with these stays (i.e., nearly a 150% 
increase in total charges between 2000 and 2006). The increasing hospitalization 
rates are consistent with growing prevalence of obesity among pediatrics in the 
US. These findings should further emphasize the need for interventions targeted 
at mitigating and managing factors associated with the risk of T2DM (e.g., 
obesity) among children.  
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OBJECTIVES: Patients with type 2 diabetes mellitus (T2DM) are at greater risk of 
experiencing a stroke or myocardial infarction (MI) than those without T2DM. A 
systematic literature review summarized published cost estimates of stroke and 
MI to better understand the economic burden for T2DM patients experiencing 
these comorbidities. METHODS: Electronic databases (2001-2011) and conference 
abstracts (2011-2012) were searched for publications on costs, utilities, and 
quality of life in the English language. This review reports the cost estimates 
identified. Costs were converted to year 2011 pounds sterling using purchasing 
power parity data and inflation indices. RESULTS: Fifty-one studies (11 primary 
cost studies; 40 economic evaluations) were identified presenting costs 
associated with an MI and/or stroke in patients with T2DM. All studies were 
performed in adults. No studies accounted for event severity. Nine primary cost 
studies reported per-patient direct costs for the year of a nonfatal event. Cost 
estimates ranged from £5,034 to £29,034 for MI and from £1,721 to £38,448 for 
stroke. For subsequent years, cost studies reported either annual or total follow-
up costs. Annual costs for stroke ranged from £639 to £12,831; for MI, 1 study 
reported a cost of £1,605. Total follow-up costs ranged from £284 to £8,988 for 
stroke and from £284 to £1,123 for MI. Only 1 study estimated direct costs for 
fatal events: £2,463 for MI and £6,645 for stroke. None of the 11 primary cost 
studies reported indirect costs associated with MI or stroke. However, 1 of the 40 
economic evaluations identified reported indirect costs for the event year and 
subsequent years. CONCLUSIONS: Literature on costs for MI and stroke specific 
to T2DM patients is sparse, with extensive variability between estimates 
identified. Further studies are needed to provide reliable cost estimates by 
severity of stroke and MI events in T2DM patients of all ages.  
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EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS 
INSULIN GLARGINE IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE 
SETTING  
Fan CS1, Zhong J2, Sun F3, LIU F3 
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OBJECTIVES: To evaluate the short-term cost-effectiveness of Liraglutide versus 
Insulin Glargine in patients with type 2 diabetes (T2DM) using a composite 
endpoint from clinical trials and the incremental medical cost in a Chinese 
setting. METHODS: The cost-effectiveness analysis was calculated as the 
incremental cost per successfully treated patient of Liraglutide versus Insulin 
Glargine at week 26. Three cohorts of 100 patients each with Liraglutide 1.2mg, 
Liraglutide 1.8mg and Insulin Glargine were established for comparison. 
Effectiveness data of patients with T2DM achieving the composite endpoint of 
HbA1c<7.0%, no weight gain, and no hypoglycaemia at week 26 from a meta-
analysis. Safety data including hypoglycaemia and serious adverse events were 
derived from ‘Liraglutide Effect and Action in Diabetes’ trials. Medical costs 
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included the cost of drugs, needles, hypoglycaemia and serious adverse events. 
The prices of drugs and needles were accounted by Chinese market retail price. 
The costs of hypoglycaemia, serious adverse events and weight loss were 
obtained from published data. All costs were adjusted to 2012 Chinese value 
based on China Consumer Price Index. Results were calculated as the difference 
of total expenditures of Liraglutide versus Insulin Glargine divided by the 
difference of patients achieving target. One-way sensitivity analyses were 
performed. RESULTS: The total cohort cost was CNY 1,658,112 (Liraglutide 
1.8mg), 1,101,812 (Liraglutide 1.2mg), and 881,326 (Insulin Glargine). Number of 
patients successfully achieving the composite endpoint was 40 (Liraglutide 
1.8mg), 32 (Liraglutide 1.2mg), and 15 (Insulin Glargine).Thus incremental cost 
per successfully treated patient was CNY 12,970 and CNY 31,071 for Liraglutide 
1.2mg and 1.8mg versus Insulin Glargine respectively. Sensitivity analyses of the 
safety parameters suggested results were robust. CONCLUSIONS: Liraglutide was 
a cost-effective treatment approach versus Insulin Glargine for treating T2DM in 
a Chinese setting. The incremental costs were less than CNY 37,784 of estimated 
China GDP per capita in 2012.  
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OBJECTIVES: To determine the prevalence of HMG-CoA reductase inhibitor 
medication use (i.e. “statin” drugs), assessing both prescribing rates and patent 
adherence to therapy, among a population of older Medicaid beneficiaries having 
type 2 diabetes in Rhode Island. Current prescribing and adherence rates were 
contrasted with an optimal use scenario using a Markov model, considering cost 
and benefit as measured in terms of predicted reductions in the incidence of 
fatal and non-fatal ischemic stroke. METHODS: We simulated expanded statin 
utilization among Rhode Island Medicaid beneficiaries age 65 or older having 
type 2 diabetes, evaluating the cost-effectiveness of increased utilization  
of statin medications. The benefit of statin use was focused on decreased stroke 
risk. Transition probabilities were derived from risk estimates generated  
for stroke, calculated from the General Practice Research Database across 
stratified gender and age groups in a cohort of 24,835 people with type 2 
diabetes. Cost-effectiveness analysis was used to project costs and benefits of 
increased levels of statin utilization contrasted with current levels of statin 
utilization. RESULTS: Premised upon the population's (N = 4,217) actual 
utilization of statin medications, predicted outcomes over a 5-year period 
included 338.53 acute stroke events; 46.69 fatal stroke events; 1,506.17 deaths 
from other causes, with a total 5-year cost of drug therapy estimated to be 
$265,832. Based upon the optimal statin use scenario, predicted outcomes 
included 272.87 acute stroke events; 37.49 fatal stroke events; and 1,508.20 
deaths from other causes, with a 5-year cost of drug therapy estimated to be 
$724,871. The resulting cost per stroke avoided was $6,991, while the cost per 
fatal stroke avoided was $49,858. CONCLUSIONS: From the perspective of the 
Medicaid payer, improving statin drug utilization in this population of older 
Medicaid-enrolled patients having type 2 diabetes is a cost-effective intervention 
for preventing ischemic stroke.  
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OBJECTIVES: To evaluate the cost-effectiveness of Liraglutide 1.2mg once daily 
versus oral antidiabetic drugs (OAD) in patients with type 2 diabetes (T2DM) 
achieving a composite endpoint of HbA1c<7.0%, no weight gain, and no 
hypoglycaemia at week 26 in a Chinese setting. METHODS: This short-term cost-
effectiveness study compared Liraglutide with Rosiglitazone, Glimepiride and 
Sitagliptin respectively. Effectiveness data of patients with T2DM achieving the 
composite endpoint of HbA1c<7.0%, no weight gain, and no hypoglycaemia at 
week 26 were derived from a meta-analysis (Zinman et al. 2012). Safety data 
were obtained from randomized, controlled, phase 3 trials including Liraglutide 
Effect and Action in Diabetes (LEAD) 1, LEAD2 and 1860 trial. Medical costs 
included the cost of drugs, needles, hypoglycaemia and serious adverse events. 
The prices of drugs and needles were accounted by the market retail price 
published by National Development and Reform Commission. The costs of 
hypoglycaemia, serious adverse event and weight loss were obtained from 
published data. All costs were adjusted to 2012 Chinese value based on China 
Consumer Price Index. Results were calculated as the difference of total 
expenditures of liraglutide versus comparators divided by the different number 
of patients achieving the target. One way sensitivity analysis was performed. 
RESULTS: Within 26 weeks, comparing with Rosiglitazone, Glimepiride and 
Sitagliptin, Liraglutide 1.2mg made 26, 24 and 21 additional patients achieve the 
composite endpoint among every 100 patients respectively. The incremental cost 
per successfully treated patient with Liraglutide 1.2mg was CNY 20,145, CNY 
26,899, and CNY 33,561 versus Glimepiride, Rosiglitazone, and Sitagliptin 
respectively. Sensitivity analyses demonstrated robustness of the results. 
CONCLUSIONS: This analysis demonstrated that Liraglutide was cost-effective 
compared to Glimepiride, Rosiglitazone, and Sitagliptin in a Chinese setting. The 
incremental costs were less than CNY 37,784 of estimated China GDP per capita 
in 2012.  
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OBJECTIVES: According to World Health Organisation, type-2 diabetes has 
recently escalated in all age groups and is now being identified in younger and 
younger age groups, including adolescents and children, especially in high-risk 
population. This underscores the need for mass awareness and screening 
programmes to detect diabetes at an early stage and early age cost effectively. 
For this purpose we have planned to use a simplified Indian Diabetes Risk Score 
[IDRS] for prediction of diabetes in young adolescents of Bharati Vidyapeeth 
Deemed University Medical College. METHODS: A total of 261 students of said 
Medical College will be screened using IDRS which includes age, family history of 
diabetes, exercise status and Waist circumference. After scoring them they will 
be categorised into mild, moderate and high risk group. In students who are 
having score more than 50, Random Capillary Blood Glucose (RCBG) were 
assessed with the help of glucometer. RESULTS: We have assessed 261 students 
till now. It was observed that 5% ,55% & 38% students in high, Moderate & Low 
risk group respectively for developing type 2 D.M. Mean abdominal obesity in 
high risk students was 101.95± 5.76 as compared to 79.17 ± 11.08 in moderate and 
low risk students(p<0.0001). Family history of diabetes in either or both parents 
was present in 25% students. 63% students were having sedentary lifestyle. Mean 
RCBG in students having score more than 50 was 97.33 ±9.68 mg/dl. Also, 3 
students were having RCBG >103mg/dl. CONCLUSIONS: This underscores the 
need for further investigations. IDRS is the simplest way to screen large 
population. To prevent and to postpone the risk of type 2 diabetes mellitus, 
health education programme, exercise and diet planning can be recommended 
for these students.Thus this mayprove as a cost effective solution of detection of 
risk of type-2 diabetes mellitus.  
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AND GLIBENCLAMIDE) WITH METFORMIN IN DIABETES IN  
COLOMBIA  
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OBJECTIVES: To Analyze the cost-effectiveness of using oral hypoglycemic 
agents (linagliptin, saxagliptin, sitagliptin, vildagliptin, glimepiride and 
glibenclamide) each associated with metformin, to control type-2 diabetes 
mellitus in patients with inadequate glycemic control, from a third-party’s payer 
perspective. METHODS: A Monte Carlo-type Markov model was used to simulate 
disease natural history. The outcomes of interest were fatal infarct, acute 
myocardial infarction, stroke, nephropathy, moderate or severe hypoglycemia 
and changing of treatment, expressed in years of life (LY). Drug costs were taken 
from market average at prices for 2012 expressed in Colombian pesos. Direct 
medical costs were taken from insurers and individual health benefit records 
(SISMED). A discount rate of 5% was applied both to cost and outcomes. 
RESULTS: As a main outcome the measures of life years (LY) are nearly similar 
for each combined treatment. However linagliptin is barely a most effective 
treatment with 13.71 life years discounted, followed by sitagliptin and 
vildagliptin with 13.70 and 13.60 life years discounted respectively. Similarly, 
linagliptin is the least expensive (COP$69,396,763 discounted annually) while 
saxagliptin and vildagliptin have a cost of COP$71,941,693 and COP$71,713,900 
discounted, respectively. It was found that linagliptin, vildagliptin and sitagliptin 
are nearly similar with respect to life years (LY) and each one is placed below the 
efficient frontier. Among the oral hypoglycemic agents analyzed, only three 
(linagliptin, vildagliptin and sitagliptin) are cost-effectives, being linagliptin the 
most. Glibenclamide is the only technology included in the Colombian health-
care benefits plan and is the least effective and the most expensive one. 
CONCLUSIONS: Linagliptin, sitagliptin and vildagliptin each one added to 
metformin is nearly similar with respect to life years (LY) and to cost-effectives. 
Linagliptin appears to be an advisable option due to its lower cost and its fewer 
macro and micro vascular events, for diabetic patients with inadequate glycemic 
control in Colombia.  
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OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from 
human soluble insulin (HI) to insulin aspart (IAsp) in patients with type 2 
diabetes mellitus (T2DM) in a Chinese setting. METHODS: A published and 
validated computer simulation model of diabetes (CORE Diabetes Model) was 
used to project long-term (30 years) life expectancy, quality-adjusted life years 
(QALY) and direct medical costs. Baseline cohort characteristics and treatment 
effects were based on Asian subgroup (n=154, including patients from China, 
Bangladesh, India, Pakistan, Indonesia, South Korea, Malaysia, Philippines, 
Singapore and Taiwan) in A1chieve study which is a prospective, multi-center, 
open-label, non-interventional, 24-week observational study. Treatment costs 
were derived from drug retail prices in Chinese market. The diabetes 
management and complication costs were obtained from Chinese published 
data. Projections were made from a societal perspective and an annual 
